Welcome to our dedicated page for Cryoport news (Ticker: CYRX), a resource for investors and traders seeking the latest updates and insights on Cryoport stock.
Cryoport, Inc. reports developments in temperature-controlled supply chain solutions for the life sciences, with recurring updates tied to regenerative medicine and cell and gene therapy support. Its platform includes the Cryoportal® Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, cryopreservation services and cryogenic systems.
Company news commonly covers quarterly and annual operating results, revenue guidance, clinical-trial and commercial therapy support, Life Sciences Services and Life Sciences Products activity, MVE Biological Solutions cryogenic systems, product introductions such as Fusion freezers, and quality or regulatory certifications for therapeutic-cell transport.
Cryoport (NASDAQ: CYRX) reported Q1 2026 revenue of $47.8M, up 16% year‑over‑year, and raised full‑year revenue guidance to $192M–$196M. Commercial CGT revenue grew 26% to $9.1M; the company supported 766 clinical trials and 21 commercial therapies as of March 31, 2026. Adjusted EBITDA from continuing operations improved by $2.2M year‑over‑year to negative $0.6M. Cash and short‑term investments totaled $403.6M. Operational expansions planned in Paris (Q3) and Santa Ana (Q4) 2026.
Cryoport (Nasdaq: CYRX) will report first quarter 2026 financial results after U.S. markets close on Monday, May 4, 2026. A "Cryoport First Quarter 2026 in Review" document will be released at 4:05 p.m. ET, followed by a Q&A conference call at 5:00 p.m. ET.
A slide deck will accompany the call; a live webcast and dial-in details are available on the company's Investor Relations site, and replays will be posted and available by phone through May 11, 2026.
Cryoport (NASDAQ: CYRX) reported FY2025 revenue of $176.2 million, up 12% year-over-year and above prior guidance, with Life Sciences Services revenue of $96.5 million (+18%) and Life Sciences Products revenue of $79.7 million (+7%).
The company supported a record 760 clinical trials and 20 commercial therapies, ended FY2025 with $411.2 million in cash and provided 2026 revenue guidance of $190.0M–$194.0M (8%–10% growth).
Cryoport (Nasdaq: CYRX) will report fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026 after U.S. markets close.
Management will issue a review document at 4:05 p.m. ET and host a questions-and-answers conference call at 5:00 p.m. ET with an accompanying slide deck; replay available through March 10, 2026.
Cryoport (NASDAQ: CYRX) launched the MVE Fusion® 800 Series, a lab-sized self-sustaining cryogenic freezer designed for space-constrained environments. The Fusion 800 eliminates the need for a continuous liquid nitrogen supply, delivers steady-state temperatures at or below -150°C, and fits through standard doorways at 32 inches wide. The technology is ISBER award-winning and aimed at research facilities, hospital pharmacies, biorepositories, and blood and tissue banks.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) reported Q3 2025 revenue of $44.2M, up 15% year‑over‑year, and raised full‑year continuing operations revenue guidance to $170.0–$174.0M. Commercial cell & gene therapy revenue grew 36% to $8.3M; Life Sciences Services revenue rose 16% and Life Sciences Products revenue rose 15% in Q3. Gross margin improved to 48.2% in Q3. Adjusted EBITDA from continuing operations narrowed to a $0.6M loss in Q3. Cryoport held $421.3M cash and completed share repurchases of 483,397 shares for $3.7M. The company noted strategic moves including a new Paris Global Supply Chain Center, MVE product launches, and a DHL partnership.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (NASDAQ: CYRX) announced that Cryoport Systems achieved ISO 21973:2020 certification, the international standard for transport of human cells for therapeutic use, on October 30, 2025.
The company participated in developing the standard, says the certification strengthens traceability, environmental control, and chain-of-custody safeguards for cell and gene therapies and is applied across regenerative, reproductive medicine, and animal health operations. Cryoport also cites its 2025 CPHI Award for Supply Chain Excellence and points investors to a company whitepaper and website for more details.
Cryoport (Nasdaq: CYRX) will report third quarter 2025 financial results for the period ended September 30, 2025 on Tuesday, November 4, 2025 after U.S. markets close.
An earnings release and a document titled "Cryoport Third Quarter 2025 in Review" will be issued at 4:05 p.m. ET, followed by a management questions-and-answers conference call at 5:00 p.m. ET the same day. The review document and slide deck will be available in the Investor Relations section at https://ir.cryoportinc.com/news-events/ir-calendar.
The live call dial-in numbers are 1-800-717-1738 (U.S.) and 1-646-307-1865 (International) with conference ID 1120106. A replay will be available online ~three hours after the call and by dial-in until November 11, 2025 (replay numbers: 1-844-512-2921 U.S.; 1-412-317-6671 International).